Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Itraconazole and Carbamazepine on Crelosidenib PK
NCT05205447Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of crelosidenib in cholangiocarcinoma (CCA), glioma, acute myeloid leukemia (AML) and 1 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum observed plasma concentration (Cmax) of LY3410738 with/without Itraconazole, Area under the concentration-time curve from Hour 0 to last measurable concentration (AUC0-t) of LY3410738 with/without Itraconazole and 4 more. Started Jan 2022; status: terminated.
02
Drugs
crelosidenib
03
Conditions
cholangiocarcinoma (CCA)gliomaacute myeloid leukemia (AML)Solid tumors
Beyond the preview
Go deeper on NCT05205447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205447.